These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32920624)

  • 1. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology.
    Jimenez-Maggiora GA; Bruschi S; Raman R; Langford O; Donohue M; Rafii MS; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):226-233. PubMed ID: 32920624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.
    Walter S; Langford OG; Clanton TB; Jimenez-Maggiora GA; Raman R; Rafii MS; Shaffer EJ; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):234-241. PubMed ID: 32920625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD).
    Walter S; Clanton TB; Langford OG; Rafii MS; Shaffer EJ; Grill JD; Jimenez-Maggiora GA; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):219-225. PubMed ID: 32920623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview.
    Aisen PS; Sperling RA; Cummings J; Donohue MC; Langford O; Jimenez-Maggiora GA; Rissman RA; Rafii MS; Walter S; Clanton T; Raman R
    J Prev Alzheimers Dis; 2020; 7(4):208-212. PubMed ID: 32920621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.
    Langford O; Raman R; Sperling RA; Cummings J; Sun CK; Jimenez-Maggiora G; Aisen PS; Donohue MC
    J Prev Alzheimers Dis; 2020; 7(4):213-218. PubMed ID: 32920622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research.
    Porsteinsson AP; Clark ED
    J Prev Alzheimers Dis; 2020; 7(4):206-207. PubMed ID: 32920620
    [No Abstract]   [Full Text] [Related]  

  • 7. The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0.
    Ritchie CW; Muniz-Terrera G; Kivipelto M; Solomon A; Tom B; Molinuevo JL
    J Prev Alzheimers Dis; 2020; 7(1):8-13. PubMed ID: 32010920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials.
    Vermunt L; Veal CD; Ter Meulen L; Chrysostomou C; van der Flier W; Frisoni GB; Guessous I; Kivipelto M; Marizzoni M; Martinez-Lage P; Molinuevo JL; Porteous D; Ritchie K; Scheltens P; Ousset PJ; Ritchie CW; Luscan G; Brookes AJ; Visser PJ
    Alzheimers Dement; 2018 Jun; 14(6):837-842. PubMed ID: 29604264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings.
    Vermunt L; Muniz-Terrera G; Ter Meulen L; Veal C; Blennow K; Campbell A; Carrié I; Delrieu J; Fauria K; Huesa Rodríguez G; Ingala S; Jenkins N; Molinuevo JL; Ousset PJ; Porteous D; Prins ND; Solomon A; Tom BD; Zetterberg H; Zwan M; Ritchie CW; Scheltens P; Luscan G; Brookes AJ; Visser PJ;
    Alzheimers Res Ther; 2020 Jan; 12(1):8. PubMed ID: 31907067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study.
    Sato K; Niimi Y; Ihara R; Suzuki K; Toda T; Iwata A; Iwatsubo T
    J Med Internet Res; 2021 Jul; 23(7):e26284. PubMed ID: 34292159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Alzheimer's Prevention Registry: A Large Internet-Based Participant Recruitment Registry to Accelerate Referrals to Alzheimer's-Focused Studies.
    Langbaum JB; High N; Nichols J; Kettenhoven C; Reiman EM; Tariot PN
    J Prev Alzheimers Dis; 2020; 7(4):242-250. PubMed ID: 32920626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the Open Screening Programs in Recruiting Subjects to Prodromal and Mild Alzheimer's Disease Clinical Trials.
    Wójcik D; Szczechowiak K; Zboch M; Pikala M
    J Prev Alzheimers Dis; 2020; 7(4):251-255. PubMed ID: 32920627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
    Grill JD; Zhou Y; Elashoff D; Karlawish J
    Neurobiol Aging; 2016 Mar; 39():147-53. PubMed ID: 26923411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Reluctance to Share Alzheimer's Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?
    Cox CG; Ryan MM; Gillen DL; Grill JD
    J Prev Alzheimers Dis; 2021; 8(1):52-58. PubMed ID: 33336225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Accelerating Preclinical Alzheimer's Clinical Trials through a Trial-Ready Cohort with Diverse Representation.
    Lee AKW; Correia S; Salloway SP
    J Prev Alzheimers Dis; 2020; 7(4):204-205. PubMed ID: 32920619
    [No Abstract]   [Full Text] [Related]  

  • 17. Minimizing the Sample Sizes of Clinical Trials on Preclinical and Early Symptomatic Stage of Alzheimer Disease.
    Luo J; Weng H; Morris JC; Xiong C
    J Prev Alzheimers Dis; 2018; 5(2):110-119. PubMed ID: 29616704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-stage Alzheimer disease: getting trial-ready.
    Aisen PS; Jimenez-Maggiora GA; Rafii MS; Walter S; Raman R
    Nat Rev Neurol; 2022 Jul; 18(7):389-399. PubMed ID: 35379951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study.
    Sato K; Ihara R; Suzuki K; Niimi Y; Toda T; Jimenez-Maggiora G; Langford O; Donohue MC; Raman R; Aisen PS; Sperling RA; Iwata A; Iwatsubo T
    Alzheimers Dement (N Y); 2021; 7(1):e12135. PubMed ID: 33778148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.